Takeda’s Uloric Gets CV Death Warning And Restricted Indication, But No REMS

Despite advisory committee pressure, US FDA stands firm against imposing REMS targeted at gout drug’s cardiovascular risks; however, Takeda must conduct utilization study to see if labeling changes impact prescribing patterns.